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Abstract
Background: Atrial fibrillation (AF) increases risk of stroke, and although this stroke risk can be ameliorated by
warfarin therapy, some patients decline to adhere to warfarin therapy. A prospective clinical study could be
conducted to determine whether knowledge of genetic risk for AF could increase adherence to warfarin therapy
for patients who initially declined therapy. As a prelude to a potential prospective clinical study, we investigated
whether the use of genetic information to increase adherence could be cost effective.
Methods: Markov model assessed costs and utilities of two care strategies for AF patients who declined warfarin
therapy. In the usual care strategy patients received aspirin. In the test strategy genetic risk for AF was assessed
(genotype of the 4q25 locus) and some patients with a positive genetic test (≥1 risk allele) were assumed to
adhere to warfarin therapy. The remaining patients received aspirin. The incremental cost-effectiveness ratio (ICER)
was the ratio of the costs differential and the quality adjusted life-years (QALYs) differential for the two strategies.
Results: We found that the 4q25 genetic testing strategy, compared with the usual care strategy (aspirin therapy),
would be cost-effective (ICER $ 47,148) if 2.1 % or more of the test positive patients were to adhere to warfarin
therapy. The test strategy would become a cost saving strategy if 5.3 % or more of the test positive patients were
to adhere to warfarin therapy. If 20 % of test positive patients were to adhere to warfarin therapy in a hypothetical
cohort of 1000 patients, 7 stroke events would be prevented and 3 extra-cranial major bleeding events would be
caused over 5 years, resulting in a cost savings of ~ $250,000 and a net gain of 9 QALYs.
Discussion: A clinical study to assess the impact of patient knowledge of genetic risk of AF on adherence to
warfarin therapy would be merited because even a modest increase in patient adherence would make a genetic
testing strategy cost-effective.
Conclusion: Providing patients who declined warfarin therapy with information about their genetic risk of AF
would be cost effective if this genetic risk information resulted in modest increases in adherence.
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Background
Atrial fibrillation (AF) is a common heart rhythm disorder
affecting about 2.4 million people in the US [1, 2], and this
number is projected to exceed 5.6 million by 2050 [3]. AF
is associated with a 5-fold greater risk of embolic stroke
[4, 5] and accounts for 75,000 to 100,000 strokes per year
in the US [4]. The risk of stroke due to AF can be reduced
by about 50 % with oral anticoagulants such as warfarin
[6, 7], and current American Heart Association and
American Stroke Association (AHA/ASA) guidelines rec-
ommend prophylactic therapy with warfarin for high and
moderate risk AF patients [8]. Despite strong evidence
supporting its efficacy, adherence to warfarin therapy is
low—among patients who started warfarin therapy for AF,
more than 1 in 4 patients discontinue warfarin therapy
within one year [9, 10]. Low adherence to warfarin therapy
is driven by patient concerns about potential bleeding
events and the need for continued periodic blood tests* Correspondence: dov.shiffman@questdiagnostics.com
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to monitor the patient’s response to warfarin [11–14].
Any strategy that would increase adherence to warfarin
therapy among eligible AF patients has the potential to
prevent fatal and non-fatal stroke events. Strategies for in-
creasing adherence to warfarin that have been previously
investigated include counseling [15, 16], the use of deci-
sion aids [16], as well as self-testing and self-management
programs [17]. Providing patients with information about
their genetic-based risks also has the potential to improve
adherence and ultimately clinical outcomes. A recent
study reported that patients with a genetic diagnosis of fa-
milial hypercholesterolemia were ~50 % more adherent to
treatment than were patients without a genetic diagnosis
[18]. Similarly, patients’ knowledge of genetic test results
increased adherence (63 vs. 45 %) to statin therapy in the
AKROBATS study [19].
Since gene variants in the 4q25 region of the human
genome are associated with increased risk of AF and
stroke [20], providing 4q25 genetic test results to pa-
tients might increase adherence to warfarin therapy. If
this strategy could be cost effective, it might justify con-
ducting a clinical trial to test the hypothesis that genetic
test results would increase adherence to warfarin ther-
apy, which may lead to a lower incidence of preventable
strokes. In order to provide cost effectiveness estimates
that could be used to justify or design such a clinical
trial, we investigated whether the use of genetic informa-
tion to increase adherence could be cost effective over a
range of adherence rates.
Methods
Model structure and overview
Our analysis considered a hypothetical population of 1000
patients with AF who were prescribed warfarin to prevent
future ischemic stroke events but who declined to adhere
to warfarin therapy. We developed a Markov model to
evaluate the payer-perspective cost-effectiveness of two
patient care strategies (Fig. 1). One strategy is usual care:
patients who refused warfarin therapy received aspirin
therapy. The other strategy is a test strategy: patients were
tested for genotypes of two variants in the 4q25 locus
(rs2200733 and rs10033464). A fraction of patients with
positive test results (having at least 1 risk allele of either
variant) were assumed to be motivated to adhere to war-
farin therapy. The remaining patients in the test strategy
received aspirin therapy. The model compared expected
costs and outcomes of these two strategies. Incremental
cost-effectiveness ratios (ICERs) were calculated as the dif-
ference in costs between the usual care strategy and the
test strategy divided by the difference in outcomes
(expressed in quality adjusted life years, (QALYs) between
the two strategies.
The model (Fig. 1) estimates the number of fatal and
non-fatal stroke events, fatal and non-fatal major bleed-
ing events, costs for drug and hospitalization, as well as
QALYs in each strategy over a 5-year horizon using a 1-
year cycle time. We assumed that warfarin reduced the
annual rate of stroke compared with aspirin [21], that
the rate of major bleeding events was lower among as-
pirin users compared with warfarin users [21], and that
40 % of the patients will have a positive genetic test re-
sult, based on the reported allele frequencies for these
genetic variants [20].
The incidence of stroke and major bleeding events was
calculated for each strategy over a 5 year time horizon
using annual event rates for warfarin and aspirin as ap-
propriate. We assumed that warfarin therapy will be dis-
continued for those patients who would experience an
intracranial bleeding or other major bleeding event and
that those patients on aspirin therapy would convert to
warfarin therapy after an ischemic stroke event. For both
strategies, we assumed that patients who initially de-
clined warfarin therapy would convert to warfarin at an
annual rate of 2.5 %. This annual rate of conversion to
warfarin would be 2-fold more likely for test-positive pa-
tients who initially declined warfarin and 2-fold less
likely for test-negative patients. One-time and subse-
quent monthly costs of stroke and major bleeding events
























Fig. 1 Schematic representation of patient care strategies and Markov model. Diamonds represent decision nodes, ovals represent Markov states.
Arrows represent potential transitions between decision nodes and states. Abbreviations: AFA, atrial fibrillation patients on aspirin therapy; AFW,
atrial fibrillation patients on warfarin therapy
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discount rate was applied to costs and utilities. Patient
utility estimates for stroke, intracranial bleeding, and
other major bleeding events were based on published es-
timates. Patients with fatal events were assigned a utility
weight of 0. A summary of base case event rates, util-
ities, and costs as well as the respective sources for these
values is provided in Table 1.
Sensitivity analyses
The adherence rates to warfarin among those with a
positive 4q25 test result were varied from 1 to 50 %
using base-case values. Sensitivity analyses were per-
formed to examine the effect of varying key param-
eter estimates. One-way sensitivity analysis included
the following parameters: the annual rate of stroke
among aspirin users (varied between 3 and 6 %), the
risk reduction of stroke by warfarin compared with
aspirin (0.37 to 0.63), the annual rate of major bleeds
among warfarin users (2 to 4 %), the relative risk of
major bleeds by aspirin compared with warfarin (0.5
to 0.7), the cost of genetic testing ($50 to $200), the
costs associated with events (strokes, major bleeds)
and drugs (varied simultaneously 50 % above and
below the base-case values), and utility estimates of
the non-fatal states in the model (varied simultan-
eously 20 % above and below the base-case values). A
probabilistic sensitivity analysis (PSA) was performed
using a Monte Carlo simulation of 10,000 trials by
drawing the values of the baseline parameters from
triangular distributions. The contribution of baseline
parameters to the variation observed in PSA was eval-
uated from the correlation between the variance of
Table 1 Model Variables: base case patient probabilities, costs, and utility estimates
Variable Base-Case Range Reference
Probabilities
Baseline rate of stroke on aspirin, %/year 4.5 3–6 [23, 24]
Relative risk of stroke with warfarin compared with aspirin 0.48 0.37–0.63 [23, 24]
Baseline rate of major hemorrhage (including ICH) on warfarin, %/year 2.5 2–4 [23, 24]
Relative risk of hemorrhage with aspirin compared with warfarin 0.59 0.50–0.70 [23]
Fraction of ICH among major hemorrhage events 0.2 NA [22]
Fraction of fatal strokes among stroke events on warfarin 0.082 NA [24]
Fraction of fatal strokes among stroke events on aspirin 0.179 NA [24]
Fraction of fatal events among ICH 0.364 NA [25]
Fraction of fatal major hemorrhages (excluding ICH) 0.049 NA [25]
Costs ($)
Warfarin annual cost 180 ±50 % [24]
Aspirin annual cost 10 ±50 % [24]
Fatal ischemic stroke 12130 ±50 % Assumption, based on [24]
Average one-time cost of non-fatal stroke on warfarin 9667 ±50 % Calculated based on [24]
Average monthly cost of non-fatal stroke on warfarin 2652 ±50 % Calculated based on [24]
Average one-time cost of non-fatal stroke on aspirin 9610 ±50 % Calculated based on [24]
Average monthly cost of non-fatal stroke on aspirin 2168 ±50 % Calculated based on [24]
Intracoronary hemorrhage (ICH) one-time cost 31810 ±50 % [24, 26, 27]
Intracoronary hemorrhage (ICH) monthly costs 4690 ±50 % [24, 26, 27]
Major hemorrhage (excluding ICH) 3620 ±50 % [24, 26, 27]
Utilities
Healthy on warfarin 0.987 unchanged [28, 29]
Healthy on aspirin 0.998 unchanged [28, 29]
Non-fatal stroke on warfarin, weighted average 0.476 ±20 % [24]
Non-fatal stroke on aspirin, weighted average 0.426 ±20 % [24]
Non-fatal ICH 0.4 ±20 % Assumption
Recurrent stroke 0.12 ±20 % [29]
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We estimated the costs and utilities over a 5 year hori-
zon of two health-care strategies among 1000 patients
with AF who were prescribed warfarin to prevent future
ischemic stroke events but who had declined warfarin
therapy. The first strategy was usual care (aspirin ther-
apy and no genetic test). The second strategy (test strat-
egy) used genetic testing for risk of AF to motivate
patients to adhere to the prescribed warfarin therapy
(Fig. 1). We modeled testing of two genetic variants as-
sociated with risk of AF in the 4q25 locus (rs2200733
and rs10033464). We assumed that those who carry at
least 1 risk allele of either variant (test positive) would
be motivated to adhere to warfarin therapy. We first in-
vestigated the fraction of the test positive patients that
would need to adhere to warfarin therapy in order to
make the test strategy cost effective. We found that
under the base-case assumptions (Table 1), the test strat-
egy would be cost-effective compared with the usual
care (cost/QALY = $47,148) if 2.1 % or more of the test
positive patients choose to adhere to warfarin therapy.
The test strategy would become a cost saving strategy if
more than 5.3 % of the test positive patients adhere to
warfarin therapy (Fig. 2). And, if 20 % of the test positive
patients adhere to warfarin therapy, 7 stroke events
would be prevented and 3 extra-cranial major bleeding
events would be caused for every 1000 patients tested.
That is, the test strategy would dominate the usual care
strategy: the test strategy would result in better out-
comes (a net gain of 9 QALYs) and lower costs (a net
saving of ~ $250,000) over a 5 year horizon compared
with the usual care strategy (Table 2).
Sensitivity analyses
We examined the effect of the uncertainty in the input
parameters on the model outcome by varying individual
parameters from their baseline values. We used a 5.25 %
adherence rate in the model to investigate the effect of
baseline parameters when adherence rate would be cost
neutral. We found that changing the input parameters
had little effect on the cost-effectiveness of the test strat-
egy compared with the usual care. When the parameters
were within the ranges listed in Table 1, the test strategy
remained cost effective (ICER < $47,000, Fig. 3). More-
over, varying the medical cost estimates, the bleeding
rate among warfarin users, the relative bleeding rate
among aspirin users vs. warfarin users, and the utility es-
timates all resulted in ICER estimates lower than
$20,000 at their most unfavorable limit. Using the low
Fig. 2 Adherence to warfarin therapy among test-positive patients
and cost/QALY. The cost-effectiveness of genetic testing (ICER in US
dollars) as a function of the initial rate of adherance to warfarin among
test positive patients who initially decline warfarin therapy
Table 2 Cost savings and utility gains of the test strategy
compared with the usual care strategy for different adherence
assumptions for 1000 patients














Fig. 3 One-way sensitivity analysis. The effect of varying baseline
parameters over clinically and economically relevant ranges on ICER.
Parameter values used are indicated to the left and to the right of
each blue bar. Abbreviation used: A, asprin; W, warfarin
Shiffman et al. BMC Cardiovascular Disorders  (2015) 15:104 Page 4 of 7
end for the annual rate of stroke among aspirin users
(3 %, compared with the baseline value of 4.5 %) resulted
in an ICER of ~ $40,000, which was the largest ICER
range for any individual baseline parameter. Since the
rate of stroke events differs among individuals according
to their CHADS2 score [24], we investigated QALY
gained and ICERs in a model for patients with different
CHADS2 scores (Fig. 4). When the test strategy was
compared with the usual care strategy among patients
with a CHADS2 score of 3 and greater, the test strategy
would be dominating the usual care strategy: it would be
cost saving and result in progressively more QALYs
gained compared with the usual care as CHADS2 score
increased.
Using a probabilistic sensitivity analysis we investi-
gated the contribution of each of these parameters to
the overall variability of the ICER estimates. We found
that 3 input parameters (the cost of genetic testing, an-
nual stroke rate among AF patients who use aspirin, and
the risk reduction of warfarin compared with aspirin) to-
gether account for more than 80 % of the variability in
the model (Fig. 5). Assuming 20 % of the test positive
patients adhered to warfarin therapy the test strategy
was almost always (96.8 %) associated with lower cost
and more QALYs than the usual care strategy (Fig. 6).
Discussion
We compared the usual care strategy with a strategy that
used genetic testing to motivate AF patients who de-
clined physician prescribed warfarin therapy to recon-
sider and initiate therapy. We found that the test
strategy could be cost effective even if only 2.1 % of test
positive individuals adhered to warfarin therapy over a
5 year horizon. If less than 2 % of test positive individ-
uals would adhere to warfarin therapy, this strategy be-
comes prohibitively expensive, costing more than
$100,000 per QALY if adherence were to fall below 1 %.
However, if adherence were to be greater than 5.3 %, this
genetic test strategy would be cost-saving under the
base-case assumptions.
A 5.3 % increase in adherence in response to genetic
test information is smaller than what has been reported
by in real-world studies. For example, among patients
who were identified as having hypercholesterolemia
based on their blood cholesterol levels, adherence to sta-
tin medication went up from 39 to 93 % following a gen-
etic confirmation of their diagnosis [18]. Similarly,
among all-comers with a newly-prescribed statin ther-
apy, adherence increased from 45 to 63 % following gen-
etic testing [19]. Thus, it seems that genetic testing
results have the potential to increases in adherence of
greater magnitude than that in the model we present.
The specific effect of genetic testing on adherence to
anticoagulation among patients with AF after genetic
testing would need to be determined in a clinical study.
Fig. 4 QALYs gained (per 1000 patients) and ICERs in patients with
different CHADS2 scores
Fig. 5 Probabilistic sensitivity analysis for the test strategy compared
with the usual care: contribution of baseline parameter variability to
overall model variability
Fig. 6 Probabilistic sensitivity analysis for the test strategy compared
with the usual care strategy assuming 20 % of the test positive
patients adhered to warfarin therapy. The cost-effectiveness plane
shows the effect of simultaneously varying all model parameters on
incremental cost (per 1000 patients, vertical axis) and incremental
effectiveness (per 1000 patients, horizontal axis) in 10,000 Monte
Carlo simulations
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The model baseline parameters were based on pub-
lished information. The effect of these parameters on
the ICERs predicted by the model was modest. The low
end of annual rate of stroke events among AF patients
who use aspirin (but decline warfarin) resulted in the
biggest ICER using baseline parameters. That is, if an-
nual stroke rate among AF patients on aspirin was 3 %,
the ICER would be ~ $47,000, however if the annual rate
of stroke was at the high end (6 %) the genetic testing
strategy would be dominating (cost-saving with better
outcomes). Interestingly, if the annual rate of stroke
among aspirin users were to be as low as 2 %, the num-
ber of strokes prevented by warfarin treatment would be
offset by an equal number of major bleeds caused by
warfarin treatment (1.5) regardless of treatment strategy.
Conversely, a higher rate of strokes in subgroups of pa-
tients, which can be estimated by risk scores such as
CHADS2, would make the test strategy more cost
saving and gain more QALYs compared with the
usual care strategy.
This study has several potential limitations. First, this
study is based on a theoretical patient cohort and there-
fore used baseline parameters that were established in
other real-life cohorts. Deviation from these baseline
parameter estimates could affect the results. However,
our sensitivity analyses established that variations in
these parameters have only a small effect on the conclu-
sions of this study. We found that the cost of the genetic
test had the greatest influence on the range of total
costs. We believe that the range of costs investigated
($50 to $200) was reasonable, because the genetic test
considered in this study involved genotyping two single
nucleotide polymorphisms (SNPs). And Medicare reim-
bursement for two SNPs was ~ $100 in 2013—this is
based on the combined reimbursement for the Factor V
Leiden SNP and for the Factor II (20210G > A) SNP
[31]. We have based all other medical costs on published
2005 estimates [25]. However, inflating these costs to
2014 would result in more favorable outcome for the
test strategy since the test strategy results in fewer
events than the usual care strategy for any adherence
rate. Second, we focused our analysis on adherence to
warfarin as an oral anticoagulant. We believe an investi-
gation of adherence to warfarin is important because
warfarin remains first line therapy (recommendation 1A)
in the 2014 AHA/ACC guidelines for the management
of patients with atrial fibrillation [30]. New oral antico-
agulants (NOACs: dabigatran, rivaroxaban, and apixa-
ban) which are now available as anticoagulant option for
some AF patients received a 1B recommendation. Pa-
tient adherence to NOACs is not likely better than to
warfarin [31], presumably because bleeding event rates
for warfarin are largely not different than that for most
NOACs [32]. Moreover, the lack of approved antidote to
NOACs can deter some patients from adhering to ther-
apy. Third, we assumed the frequency of individuals who
are carriers of a 4q25 risk allele (test positive) to be
40 %. This assumption is based on the reported allele
frequencies of rs2200733 and rs10033464 in populations
of European ancestry. The fraction of test positive indi-
viduals could vary in populations with a different ethnic
ancestry. For example, among Yoruban in Ibadan, Nigeria,
the fraction of test positive patients would be 86 % [33].
We elected to use the test positive information for
European ancestry patients because most of the genetic
association studies supporting the association of these
SNPs with risk of AF were conducted in these popula-
tions. Our model could be easily adopted for other ex-
pected test positive fractions. Given these limitations, the
results of this study should be cautiously considered when
trying to extrapolate to real-life studies.
Conclusions
In conclusion, we have demonstrated that under a wide
range of input parameters, genetic testing to motivate
adherence to warfarin therapy among AF patients eli-
gible for this therapy would be cost effective. The range
of cost effective adherence rates identified in this model
could be used to aid in design of a clinical study that
would test whether providing patients with information
about their genetic AF risk would improve their adher-
ence to warfarin therapy.
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